Plasma Protease C1-inhibitor Market Size Outlook,Share and Growth Stance Forecast 2022-2031

The Plasma Protease C1-inhibitor Treatment Market is expected to experience a significant growth over the forecast period due to the growing incidence of hereditary angioedema (HAE). Hereditary angioedema is a potentially life-threatening genetic condition with incidence between 1 in 10,000 and 1 in 50,000 people according to HAE International (HAEi), the global umbrella organization for the world’s HAE patient groups.

Additionally, increasing R&D investments, discovery of inhibitor drugs, increasing product approvals promising pipeline drugs and novel therapies for the treatment of hereditary angioedema are the few other factors driving the market globally.

Get a Sample Copy of this Report with Graphs and Charts: https://www.sdki.jp/sample-request-89152

Key Market Trends

Selective Bradykinin B2 Receptor Antagonist Segment is Expected to Witness Healthy CAGR Over the Forecast Period


A bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE). In 2011, Icatibant (Firazyr), a selective bradykinin B2 receptor antagonist, was approved by the US Food and Drug Administration for treatment of acute attacks HAE in adults. Approval was based on 3 double-blind, randomized, controlled clinical trials known as For Angioedema Subcutaneous Treatment (FAST) 1, 2, and 3.

In September 2019, Pharvaris also received a USD 66 Million Series B Financing to Advance the Clinical Development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2-receptor-mediated indications.

Plasma Protease C1-inhibitor Market
Transplant Diagnostics Market
Plantar Fasciitis Treatment Market
Prosthetic Heart Valve Market
Electric Vehicle Infrastructure Market
UPS Market
Natural Gas Compressors Market
India LNG Market
GCC Switchgear Market
Building Energy Management Solutions Market

Related posts

Leave a Comment